Jan 13 2010
Independent studies done by universities and corporations have illustrated a remarkable increase in the yield of viable stem cells after cryopreservation using AAGP™ in the freeze-thaw process. One future approach to increasing diabetics’ insulin production is related to an ability to convert their stem cells into islet cells for transplantation. The feasibility of this procedure is dependent upon the amount of functioning islet cells that can be derived from the patient’s stem cells. This is where AAGP™ can make a very beneficial contribution.
The Edmonton Protocol has successfully transplanted islet cells from donated pancreases into the liver and subsequently produced insulin in the patients. This protocol has been adopted by hospitals around the world, however, the lack of donors and the requirement for anti-rejection drugs severely restricts its use on a wide spread basis. The scientific community has been aggressively pursuing the ability to differentiate a person’s stem cells into islet cells. This achievement will provide a compatible source of islet cells that can be used in conjunction with the Edmonton Protocol. In order for this exciting new treatment to be both successful and economic on a universal scale, it is imperative that a very high recovery rate of islet cells is achieved. ProtoKinetix has demonstrated that it will be playing a pivotal role in the future treatment of diabetes.
SOURCE ProtoKinetix, Inc.
Study reveals slower fat gain in babies exposed to gestational diabetes